Top Markets
Coin of the day
PT Tempo Scan Pacific Tbk PT Tempo Scan Pacific Tbk

PT Tempo Scan Pacific Tbk

TSPC
주식 순위 #11117
PT Tempo Scan Pacific Tbk, an Indonesian company headquartered in Jakarta with... PT Tempo Scan Pacific Tbk, an Indonesian company headquartered in Jakarta with an international presence, operates primarily across three core business segments: pharmaceuticals, consumer products and cosmetics, and distribution services. Its activities encompass the trading of pharmaceutical and medical devices, alongside the manufacturing of diverse goods such as soaps, herbal products, powdered milk, food and beverages, and plastic packaging. The company also produces and markets a variety of consumer goods, cosmetic lines, and household items. Products are sold under an extensive portfolio of brands, including Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II. Beyond these, PT Tempo Scan Pacific Tbk offers a range of supplementary services, including property construction and leasing, warehousing and freight forwarding, advertising and promotion, research and development, and information technology and communication network systems. It also manages procurement, distribution, and marketing functions. Established in 1970, the company was formerly known as PT Scanchemie and functions as a subsidiary of PT Bogamulia Nagadi.
주가
$0.16403186
마지막 동기화: 2026-08-28
시가총액
$739.76M
변동 (1일)
1.47%
변동 (1년)
18.10%
국가
ID
거래 PT Tempo Scan Pacific Tbk (TSPC)

카테고리

PT Tempo Scan Pacific Tbk (TSPC)의 발행 주식 수
August 2026 기준 발행 주식 수: 0
PT Tempo Scan Pacific Tbk의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 0입니다. August 2026 말 기준 회사는 0주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
PT Tempo Scan Pacific Tbk (TSPC)의 발행 주식 수 기록 (2026 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 발행 주식 수